From the GRACE Archives - Originally Published August 26, 2009 | By Dr Pennell OK, I hope you all aren’t bored to tears by this topic by now, given...
From the GRACE Archives - Originally Published August 26, 2009 | By Dr Pennell OK, I hope you all aren’t bored to tears by this topic by now, given...
From the GRACE Archives - Originally Published August 26, 2009 | By Dr Pennell OK, I hope you all aren’t bored to tears by this topic by now, given...
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
[powerpress]
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
[powerpress]
Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
[powerpress]
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
[powerpress]
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
[powerpress]
A couple of weeks ago, I described the new concept of a "tweetchat" about lung cancer, and we're about to have our second of these tomorrow: Thursday, August 8th, at 8 PM Eastern, 5 PM Pacific time.
Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.
[powerpress]
Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]
Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
[powerpress]
The most pivotal study supporting the value of screening for lung cancer is the National Lung cancer Screening Trial (NLST), which revealed a 20% improvement in overall survival in patients with sufficiently high risk of lung cancer and who underwent an annual chest CT scans vs. chest x-ray over a three year period.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.